Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis

Despite advances in modern medicine, sepsis remains a complex syndrome that has been associated with significant morbidity and mortality. Multiple organ failure associated with sepsis leads to high mortality and morbidity. About 28 – 50% deaths have been reported in patients with sepsis. The number of sepsis patients is increasing, with considerable burden on healthcare facilities. Various factors leading to a rise in the incidence of sepsis are (1) Improvement of diagnostic procedures (2) Increase in the number of immunocompromised patients taking treatment for various autoimmune disease, carcinomas, organ transplantation (3) Advances in intensive procedures (4) Nosocomial infections (5) Extensive use of antibiotics. With the better understanding of sepsis various modalities to modify pathophysiological response of septic patients have developed. Activated protein C and low-dose corticosteroid therapy have been tried in patients, with variable results.

[1]  A. Marti-Carvajal,et al.  Human recombinant activated protein C for severe sepsis. , 2011, The Cochrane database of systematic reviews.

[2]  M. Levy,et al.  Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. , 2009, American journal of respiratory and critical care medicine.

[3]  G. Houston,et al.  Activated protein C for the treatment of severe sepsis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  G. Beilman,et al.  Adjunctive measures for treating surgical infections and sepsis. , 2009, The Surgical clinics of North America.

[5]  Y. Shibayama,et al.  Pathogenesis of focal and random hepatocellular necrosis in endotoxemia: microscopic observation in vivo. , 2008, Liver.

[6]  P. Barie,et al.  Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock , 2008, Intensive Care Medicine.

[7]  Brian H Cuthbertson,et al.  Hydrocortisone therapy for patients with septic shock. , 2008, The New England journal of medicine.

[8]  G. Bernard,et al.  Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome , 2006, Critical care.

[9]  R. Rossaint,et al.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005, The New England journal of medicine.

[10]  C. Sprung,et al.  Use of corticosteroid therapy in patients with sepsis and septic shock: An evidence-based review , 2004, Critical care medicine.

[11]  D. Annane,et al.  Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis , 2004, BMJ : British Medical Journal.

[12]  Charles Natanson,et al.  Meta-Analysis: The Effect of Steroids on Survival and Shock during Sepsis Depends on the Dose , 2004, Annals of Internal Medicine.

[13]  M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive care medicine.

[14]  H. Volk,et al.  Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. , 2003, American journal of respiratory and critical care medicine.

[15]  D. Annane,et al.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. , 2002, JAMA.

[16]  G. Bernard,et al.  Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis , 2001, Critical care medicine.

[17]  J. Helterbrand,et al.  Low levels of protein C are associated with poor outcome in severe sepsis. , 2001, Chest.

[18]  C. Esmon,et al.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis. , 2001, The New England journal of medicine.

[19]  J. Marshall,et al.  Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome , 2001, Critical care medicine.

[20]  Djillali Annane,et al.  Corticosteroids for septic shock , 2001, Critical care medicine.

[21]  J. Dhainaut,et al.  Activated protein C versus protein C in severe sepsis , 2001, Critical care medicine.

[22]  L. Bajzar.  Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[23]  K. Eckardt,et al.  Plasma cortisol levels before and during "low-dose" hydrocortisone therapy and their relationship to hemodynamic improvement in patients with septic shock , 2000, Intensive Care Medicine.

[24]  S. Tibby,et al.  Procalcitonin and cytokine levels: Relationship to organ failure and mortality in pediatric septic shock , 2000, Critical care medicine.

[25]  D. Annane,et al.  A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. , 2000, JAMA.

[26]  T. Staudinger,et al.  Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. , 1997, American journal of respiratory and critical care medicine.

[27]  D. Männel,et al.  Role of NFkappaB in the mortality of sepsis. , 1997, The Journal of clinical investigation.

[28]  M. Burdick,et al.  The Association between Mortality Rates and Decreased Concentrations of Interleukin-10 and Interleukin-1 Receptor Antagonist in the Lung Fluids of Patients with the Adult Respiratory Distress Syndrome , 1996, Annals of Internal Medicine.

[29]  C. Chopin,et al.  Coagulation inhibitor substitution during sepsis , 1995, Intensive Care Medicine.

[30]  Joseph A. DiDonato,et al.  Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.

[31]  R. Lefering,et al.  Steroid controversy in sepsis and septic shock: a meta-analysis. , 1995, Critical care medicine.

[32]  F. Stentz,et al.  Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS : plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time , 1995 .

[33]  R. Simon,et al.  Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. , 1995, The American journal of medicine.

[34]  J. Cidlowski,et al.  Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors , 1995, Molecular and cellular biology.

[35]  B. Walker,et al.  Corticosteroids and vascular tone: mapping the messenger maze. , 1992, Clinical science.

[36]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[37]  T. Calandra,et al.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. , 1991, The American journal of medicine.

[38]  A. F. Muller,et al.  Tumor necrosis factor alpha inhibits the hormonal response of the pituitary gland to hypothalamic releasing factors. , 1990, Endocrinology.

[39]  A. Chang,et al.  Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. , 1987, The Journal of clinical investigation.

[40]  C. Esmon,et al.  The roles of protein C and thrombomodulin in the regulation of blood coagulation. , 1984, The Journal of biological chemistry.

[41]  L. Axelrod.  INHIBITION OF PROSTACYCLIN PRODUCTION MEDIATES PERMISSIVE EFFECT OF GLUCOCORTICOIDS ON VASCULAR TONE Perturbations of this Mechanism Contribute to Pathogenesis of Cushing's Syndrome and Addison's Disease , 1983, The Lancet.

[42]  A. Hoitsma,et al.  Adrenocortical function: An indicator of severity of disease and survival in chronic critically ill patients , 2005, Intensive Care Medicine.

[43]  M. Ullian.  The role of corticosteriods in the regulation of vascular tone. , 1999, Cardiovascular research.

[44]  U. Stenman,et al.  Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. , 1991, Endocrinology.